Literature DB >> 3719532

Bilateral optic neuritis evolved during tamoxifen treatment.

T Pugesgaard, F E Von Eyben.   

Abstract

A 57-year-old woman developed bilateral optic neuritis after being treated for 6 months with tamoxifen in the dosage of 30 to 40 mg orally a day. As the neuritis progressed during continued treatment and no other causal explanation could be found, tamoxifen was stopped and the optic neuritis regressed. Since tamoxifen might cause optic neuritis the authors recommend the monitoring of ocular symptoms in treated patients.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3719532     DOI： 10.1002/1097-0142(19860715)58:2<383::aid-cncr2820580232>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  14 in total

1.  Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.

Authors:  V Scaioli; A Caraceni; C Martini; S Curzi; G Capri; G Luca
Journal:  J Neurooncol       Date:  2005-08-25       Impact factor: 4.130

Review 2.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

3.  Longterm remission of multiple brain metastases with tamoxifen.

Authors:  H Pors; F E von Eyben; O S Sørensen; M Larsen
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

Review 4.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

5.  [Tamoxifen retinopathy: a case series of clinical and functional data].

Authors:  C Ritter; A B Renner; J Wachtlin; N E Bechrakis; L Krause
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

6.  Phase I trial of droloxifene in patients with metastatic breast cancer.

Authors:  A U Buzdar; S Kau; G N Hortobagyi; R L Theriault; D Booser; F A Holmes; R Walters; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case.

Authors:  V Scaioli; A Caraceni; C Martini; E Palazzini; E Tarenzi; F Fulfaro; E Munzone
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 8.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 9.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 10.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.